TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: SMA Targeted Magnetic Stimulation Against Auditory Verbal Hallucinations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria for the AVH group:~* Reported AVH with a minimum frequency of at least daily occurrence, with onset more than one month ago~* Stable psychopharmacological treatment past month~Inclusion criteria for the non-AVH control group~* Reporting no occurrences of AVH for the past year~* Stable psychopharmacological treatment past month~Inclusion criteria for the healthy control group~* No life-time occurrence of AVH~* No history of psychiatric disorders as assessed with a Mini-International Neuropsychiatric Interview (M.I.N.I.)~Exclusion Criteria:~* Ferromagnetic or electromagnetic implants that may pose a risk during magnetic resonance imaging (MRI) and/or cTBS~* A history of epilepsy~* Pregnancy~* Current substance use disorder or a history of alcohol use disorder as assessed with Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT), urine samples with test for illicit drugs and Phosphatidylethanol (PEth)~* Daily benzodiazepine use~* Factors that make the participant unlikely to be able to complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Open label active cTBS (Type: EXPERIMENTAL): Four consecutive days with 40s cTBS, 100% MT over the SMA, five times a day with 50 minutes between stimulations
- active cTBS (Type: EXPERIMENTAL): One test session with 40s active cTBS, 100% MT, over the SMA in the initial double blind cross-over phase
- Sham cTBS (Type: SHAM_COMPARATOR): One test session with 40s sham cTBS, 100% MT, over the SMA in the initial double blind cross-over phase with a special sham coil that diverts the magnetic field to be only superficial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate.~* Progressive, metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy (resistant or intolerant).~* Progressive disease based on PSA progression, RECIST, or positive bone scan.~* ECOG 0 or 1.~Exclusion Criteria:~* Prior treatment with sunitinib and/or more than 1 prior chemotherapy regimen in the metastatic disease setting.~* Chemotherapy within 3 weeks.~* Impending complications from bone metastases.~* Ongoing urinary obstruction.~* Cardiac dysfunction, QTc \>470 msec.~* CNS involvement.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Treatment Arm A - sunitinib + prednisone
- B (Type: PLACEBO_COMPARATOR): Treatment Arm B - placebo + prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Femtosecond Laser for Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to comply with the treatment/follow-up schedule and requirements~* Able to understand and provide written Informed Consent~* ETDRS visual acuity equal to or worse than 20/32 (best corrected)~* Age between 50 and 80 years old~* Pupil dilates to at least 6 mm~* Subject able to fixate~* Grade 1-4 nuclear sclerotic cataract (LOCS III)~* Axial length between 22 and 26 mm~Exclusion Criteria:~* Pregnant, intending to become pregnant during course of the study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding~* Participation in a study of another device or drug within 3 months prior to study enrollment or during this study, and as per the Investigator's careful discretion, as long as not contradictory to any of the above criteria~* Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study or for which cataract surgery is contraindicated~* Anterior chamber depth (anterior corneal surface to anterior capsule margin) less than 2.5 mm via IOL Master (Zeiss).~* History of prior ocular surgery~* History of ocular trauma~* Co-existing ocular disease affecting vision~* History or current use of alpha-1 antagonist medication (e.g., Flomax)~* Known sensitivity to planned concomitant medications

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- U/S Surgery and CCC (Type: ACTIVE_COMPARATOR): Ultrasound (U/S) cataract surgery and continuous curvilinear capsulorhexis (CCC).
- FS Laser Surgery (Type: EXPERIMENTAL): For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Campylobacter Enteritis and PI-BD: Dietary Reduction in Carbohydrates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participation in the CERAMIC study (see linked protocol)~* On-going post infective bowel dysfunction (PI-BD) 3 months after confirmation of Campylobacter spp. in stool sample. This is defined as responding 'No' to the question have your bowels returned to normal since your Campylobacter infection?~* Will consent to use of data and samples acquired for CERAMIC in the analysis of CEDRIC~Exclusion Criteria:~As for CERAMIC study (so already confirmed)~* Pregnancy declared by the candidate~* History declared by the candidate of pre-existing gastrointestinal disorder, including but not limited to: Inflammatory Bowel Disease; Coeliac Disease; Pancreatitis; Gallstone disease (biliary colic, cholecystitis); Diverticulitis; Cancer of the gastrointestinal tract; Irritable Bowel Syndrome~* Reported history of previous resection of any part of the gastrointestinal tract other than appendix or gallbladder~* Intestinal stoma~* Habitual use of opiate analgesics likely to alter bowel function e.g. morphine~* Use of antibiotics in the preceding four weeks other than for treatment of index infection. Any condition where the candidate is likely to require a course of antibiotics in the next 3 months e.g. severe chronic respiratory disease, recurrent urinary tract infection, lower limb ulceration~* Inability to complete the symptom questionnaires e.g. cognitive dysfunction, limiting memory and understanding~* Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g. cognitive dysfunction, chaotic lifestyle related to substance abuse~Addition criteria for CEDRIC study:~* Use of antibiotics or prescribed probiotics during the CERAMIC study~* Failure to provide research stool samples during CERAMIC study~* Dietary practice not compatible with safe implementation of the trial diet e.g.veganism~* Medical reasons for pre-existing controlled diet that cannot be safely randomised e.g. end-stage kidney disease, diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal FODMAP arm (Type: SHAM_COMPARATOR): Low FODMAP dietary advice; participants to supplement diet with oligofructose, a poorly digested carbohydrate that will restore FODMAP content to the diet.
- Low FODMAP arm (Type: EXPERIMENTAL): Low FODMAP dietary advice; participants to supplement with maltodextrin (easily digestible carbohydrate)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Non-penetrating traumatic brain injury.~2. Age 18 (19 in Alabama) - 70 years.~3. GCS criteria on/off paralytics as specified in protocol~4. Reasonable expectation of completion of outcomes measures at a network center at six months post-injury.~5. Able to swallow oral medication or, if unable to swallow, a gastric tube or peg are placed by 23 hours after injury.~6. Reasonable expectation of enrollment within 24-hour time window.~7. English-speaking~Exclusion Criteria:~1. Intubated patients with GCS motor score = 6 and not meeting CT criteria.~2. Bilaterally fixed and dilated pupils~3. Positive pregnancy test, known pregnancy, or currently breast feeding~4. Evidence of diseases that interfere with outcome assessment~5. Current acetylcholinesterase inhibitor use (Appendix 1)~6. Imminent death or current life-threatening disease~7. Currently enrolled in another study~8. Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): Placebo tablets formulated to resemble the citicoline treatment.
- Citicoline (Type: EXPERIMENTAL): Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a histologically confirmed or presumed diagnosis of gynecologic malignancy for whom chemotherapy with paclitaxel and carboplatin is planned.~* Body Surface area \>2.0~* Patients must have adequate:~  * Renal function: Creatinine \<1.5 x Institutional upper limits of normal (ULN)~ * Bone marrow function:~    * Absolute neutrophil count (ANC) ≥ 1,500/mcl. This ANC cannot have been induced or supported by granulocyte colony stimulating factors.~   * Platelets ≥ 100,000/mcl.~ * Hepatic function:~    * Bilirubin ≤ 1.5 x ULN.~   * Aspartate aminotransferase (AST) (SGOT) ≤ 2.5 x ULN.~   * Alkaline phosphatase ≤ to 2.5 x ULN.~ * Neurologic function:~    * Neuropathy (sensory and motor) ≤ CTCAE Grade 1.~* Patients must have a Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.~* Patients must be entered within 12 weeks of diagnosis.~* Subjects must have the ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.~* Patients who have received prior chemotherapy.~* Patients with acute hepatitis or active infection that requires parenteral antibiotics.~* Patients with clinically significant cardiovascular disease. This includes:~  * Myocardial infarction or unstable angina \< 6 months prior to registration.~ * New York Heart Association (NYHA) Grade II or greater congestive heart failure~ * Serious cardiac arrhythmia requiring medication. This does not include asymptomatic, atrial fibrillation with controlled ventricular rate.~* Patients who are pregnant or nursing.~* Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study.~* Patients with known allergy to cremophor or polysorbate 80.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel + Carboplatin (Type: EXPERIMENTAL): Paclitaxel dosed by actual body surface area and not maxed at BSA 2.0. The Carboplatin dose will be calculated according to the Calvert formula using as estimated glomerular filtration rate from the Cockcroft-Gault formula and will be subject to maximum allowed doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of Adhese Universal DC in the Indirect Restorative Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-65 years~* Indication for indirect restorations (inlay, onlay) in molar or premolar - replacement of insufficient fillings (e.g. due to caries at margins, filling fracture, fracture of the tooth, poor quality of the surface, leaking margin, etc.) or extensive primary caries~* The occlusal area of the restoration must cover at least 1/3 of the occlusal area of the tooth.~* Participant wishes a restoration within the scope of the study (signed informed consent after detailed explanation and study of the patient information)~* 2-operative discomfort of the tooth to be restored should not exceed 3 on the visual analogue scale (VAS) (0=no pain, 10=maximum conceivable pain) due to temperature stimulus or bite sensitivity~* Max. 2 restorations per participant in different quadrants.~* Vital tooth~* Healthy periodontium, no active periodontitis~* Contact with adjacent teeth (at least at one side) and opposing teeth present with at least one contact point.~* Sufficient language skills~Exclusion Criteria:~* Sufficient isolation not possible, dry working field cannot be guaranteed~* Participants with a proven allergy to one of the ingredients of the materials used~* Participants with proven allergy to local anaesthetics~* High caries activity/ poor oral hygiene~* Participants with severe systemic diseases~* Pregnancy~* Nonvital tooth or tooth with irreversible pulpitis~* Indication for direct pulp capping~* Symptoms of SARS-CoV2 infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Adhese Universal DC (Type: EXPERIMENTAL): None
- Adhese Universal (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* women 18 to 50 years of age~* being seen at the University of Iowa Women's Healthcare Clinic~Exclusion Criteria:~* men

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Pregnant subjects (Type: EXPERIMENTAL): These are pregnant women that are admitted to Labor \&Delivery (L\&D) or an outpatient in the Women's Health Clinic that are being evaluated for rupture of membranes.
- Pregnant controls (Type: ACTIVE_COMPARATOR): These women will be found primarily in the Women's Health Clinic, when being seen for their routine antepartum appointments. Most of them will be recruited at about 36 weeks, since they will be having a pelvic exam at this time, as part of their routine antepartum care.
- Non pregnant controls (Type: SHAM_COMPARATOR): These women will be found in the Women's Health Clinic, when being seen for gynecology appointments. Nursing staff and the dashboard will help to identify those patients who will be having a pelvic exam.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-positive patients~* most recent CD4-count \> 250 c/μl (latest within the previous 7 months)~* anti-retroviral treatment naïve~* age \>18 years~* provide written informed consent~Exclusion Criteria:~* Pregnant and lactating women in the first week of lactation~* Symptoms of severe anemia (or haemoglobin \<5g/dl within the precious 3 months)~* Symptoms of chronic diarrhea (defined as \>= 3 stools per day of loose consistency for more than 2 weeks)~* Patients on treatment for tuberculosis~* WHO clinical stage 3 disease and CD4-count \<350 c/μl~* WHO clinical stage 4 disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anthelminthic treatment (Type: ACTIVE_COMPARATOR): Albendazol plus fix-dose Praziquantel plus Ivermectin
- HIV care, no anthelminthic treatment (Type: NO_INTERVENTION): HIV care as per Tanzanian National AIDS Control Program (NACP) guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Patient meets protocol criteria for diagnosis of IBS-C, abdominal pain, abdominal bloating and abdominal girth~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has both clinically significant findings and unexplained clinically significant alarm symptoms~* Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 290 μg linaclotide (Type: EXPERIMENTAL): Linaclotide Oral, once daily
- Matching Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo Oral, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiometabolic Risk of Shiftwork

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Day workers and shift workers at the University of Chicago, University of Chicago Medical Center, or another Chicago area medical center who have maintained their work schedule (at least 30 hours/week) for at least 6 months.~* Individuals who have been shift workers for less than 10 years; body mass index \<40 kg/m2;~* No major illness~* No history of psychiatric, endocrine, cardiac or sleep disorders~* Those with hypertension or dyslipidemia will be included if these conditions are controlled by a stable treatment.~* Women taking oral contraceptive or hormonal replacement therapy will be included only if they plan to stay on a stable regimen throughout the study.~* Age must be between 18 and 50 years~Exclusion Criteria:~* Individuals who have worked at the University of Chicago, University of Chicago Medical Center, or another Chicago area medical center in their current position for less than 6 months.~* Individuals who have been shift workers for more than 10 years~* BMI\>40 kg/m2~* Individuals with a major illness (e.g. diabetes, sleep disorder)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Shift Workers (Type: None): None
- Day Workers (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility